Community oncologists cited prior authorization as a care barrier, even as AI adoption doubled in 2026, according to the Oncology Care Index.
|Videos|March 1, 2017
Impact of a Value-Based Formulary in Three Chronic Disease Cohorts
Research presented by Kai Yeung, PharmD, PhD, scientific investigator I, Group Health Research Institute, at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.
Advertisement
Research presented by Kai Yeung, PharmD, PhD, scientific investigator I, Group Health Research Institute, at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.
Advertisement
Related to this article
Payers say NCCN guideline concordance sets a baseline for cancer coverage, but cost and formulary variation may still limit access.
Accelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.
The IRA's Medicare out-of-pocket cap is easing costs for patients with cancer, but community oncology leaders warn price cuts are straining practices.
Biomarker testing, referrals, screening, treatment access, and clinical trial barriers were examined during this recent IVBM.
Oncologists say advances in testing and treatment are outpacing staffing, pay, and access.
CDC's David A. Siegel, MD, MPH, on rising cancer diagnoses, falling deaths, and where CDC's cancer control resources go next.
Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.
Advertisement
Advertisement
Trending on AJMC
1
Tavapadon for Parkinson Disease Approved by FDA
2
Health System Pharmacies Keep Patients on GLP-1 Therapy
3
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
4
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
5